Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARCLE: Pramipexole for Major Depressive Disorder
NCT07022405Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Jan 2026
- Primary completion
- Aug 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pramipexole in major depressive disorder (MDD), sponsored by Stanford University. Started Jan 2026; status: recruiting.
02
Drugs
pramipexole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07022405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022405.